Related Experiment Videos

Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy

Rebecca G Pomerantz1, Elinor Mody, M Elaine Husni

  • 1University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Journal of Drugs in Dermatology : JDD
|April 15, 2009
PubMed

Insights

Psoriatic arthritis mutilans, a severe form of psoriatic arthritis, showed joint and skin improvement with etanercept. However, lasting deformities highlight the need for early psoriatic arthritis recognition and treatment.

Area of Science:

  • Rheumatology
  • Dermatology
  • Immunology

Background:

  • Psoriatic arthritis (PsA) is a chronic inflammatory condition linked to psoriasis.
  • Arthritis mutilans, a severe subtype of PsA, causes joint destruction and irreversible deformities.

Observation:

  • This study followed three patients with psoriatic arthritis mutilans over two years.
  • Patients received etanercept, a TNF-alpha inhibitor, for their PsA and psoriasis.

Findings:

  • Etanercept therapy led to significant improvements in both joint and skin symptoms.
  • Despite treatment, patients retained permanent deformities due to long-standing disease progression.

Implications:

  • Early recognition and treatment of PsA are crucial to prevent irreversible joint damage.
  • Dermatologists play a key role in identifying early joint symptoms in psoriasis patients, facilitating timely PsA diagnosis.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...